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Objective: We investigated the relative effects of fatigue,
depressive symptoms, and hopelessness on prognosis at 2-year
follow-up in percutaneous coronary intervention (PCI) patients.
Methods: Consecutively admitted PCI patients (n=534) treated
with paclitaxel-eluting stent as the default strategy completed the
Maastricht Questionnaire (MQ) at baseline. Apart from an
overall vital exhaustion score, the MQ also assesses fatigue
(seven items; Cronbach’s a=.87) and depressive symptoms
(seven items; Cronbach’s a=.83), with hopelessness (one item)
comprised in the depressive symptom items. Patients were
followed up for adverse clinical events (mortality and nonfatal
myocardial infarction) at 2 years. Results: At 2-year follow-up,
there were 31 clinical events. In univariable analyses, overall
vital exhaustion and depressive symptoms, but not fatigue, were
associated with adverse prognosis; in multivariable analysis,0022-3999/07/$ – see front matter D 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.jpsychores.2006.12.018
B No conflict of interest exists.
4 Corresponding author. CoRPS, Department of Medical Psychology,
Tilburg University, Warandelaan 2, PO Box 90153, 5000 LE Tilburg,
The Netherlands. Tel.: +31 13 466 2503; fax: +31 13 466 2370.
E-mail address: s.s.pedersen@uvt.nl (S.S. Pedersen).depressive symptoms [hazard ratio (HR)=2.69; 95% confidence
interval (95% CI)=1.31–5.55] remained the only predictor of
clinical outcome. Among the depressive symptoms, hopelessness
(HR=3.44; 95% CI=1.65–7.19) was the most cardiotoxic
symptom. The incidence of clinical events was higher in the
high-hopelessness patients (11% vs. 3%; P=.001) than in the
low-hopelessness patients. Hopelessness (HR=3.36; 95%
CI=1.58–7.14; P=.002) remained an independent predictor of
clinical outcome at 2 years in adjusted analysis. Conclusion:
Symptoms of depression, but not fatigue, predicted adverse
clinical events. Hopelessness was the most cardiotoxic symptom,
associated with a more than three-fold risk of clinical events
2 years post-PCI. Screening for hopelessness may lead to the
identification of high-risk patients.
D 2007 Elsevier Inc. All rights reserved.Keywords: Coronary artery disease; Depressive symptoms; Fatigue; Hopelessness; Percutaneous coronary intervention; PrognosisIntroduction
In the context of coronary artery disease (CAD), there is
an ongoing debate as to whether depressive symptoms
reflect actual depression or symptoms of underlying disease,
given the overlap between depression and somatic symp-toms, such as fatigue, trouble sleeping, and so on [1,2].
Fatigue [3–6], depression [1], and hopelessness [7,8] have
all been associated with CAD. Fatigue is a frequently
reported symptom in patients with cardiac conditions, with
prevalence rates ranging from 59% to 75% [9]. Fatigue has
been shown to precede the onset of myocardial infarction
(MI) [3] and to be a risk factor for ischemic heart disease
and mortality in healthy individuals [4]. In CAD patients,
fatigue or exhaustion confers a two-fold to three-fold
increased risk of morbidity and mortality, adjusting for
clinical risk factors including disease severity [5,6].earch 62 (2007) 455–461
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been assessed with the Maastricht Questionnaire (MQ),
which taps symptoms of exhaustion, demoralization, and
increased irritability [10]. However, evidence suggests that
the MQ assesses not only symptoms of fatigue but also
symptoms of depression [11,12]. Given that depression is a
risk factor for adverse clinical outcome in CAD [1,2,13], it
is possible that depressive symptoms, as assessed by the
MQ, may predict prognosis above and beyond fatigue.
Previous attempts addressing this issue have primarily been
performed at a conceptual level and have yielded incon-
sistent results [11,12,14–16].
Knowledge of the nature of depressive symptoms is
important for secondary prevention in order to optimize risk
stratification in clinical practice. Hence, there is a quest for
the identification of the core and most cardiotoxic depres-
sive symptoms. In epidemiological studies, hopelessness
has been associated with the progression of carotid
atherosclerosis [17,18], risk of mortality, and incidence
of MI and cancer [7,19]. Although hopelessness may
be considered a feature of depression, the strength of
association with established depression scales is weak,
suggesting that this psychological symptom should be
studied in its own right [19]. To our knowledge, only one
study has examined the role of hopelessness in the clinical
course of CAD in patients with established disease and has
found hopelessness to be associated with reduced survival
[8]. However, this study did not compare the influence of
fatigue relative to the influence of depressive symptoms
and hopelessness.
Hence, in the current study, we investigated the relative
effect of fatigue, depressive symptoms, and hopelessness on
prognosis in patients treated with percutaneous coronary
intervention (PCI).Materials and methods
Participants and study design
Consecutively admitted patients presenting with stable or
unstable angina, treated with PCI at the Erasmus Medical
Center Rotterdam (Rotterdam, The Netherlands) between
July 1, 2003, and July 1, 2004, qualified for inclusion in the
current study. Implantation with paclitaxel-eluting stent
comprised the default strategy. During this period, 845
patients were treated; patients who died within the first
4 weeks after the index procedure (n=19) or who were not
sufficiently proficient in the Dutch language to complete a
psychological questionnaire (n=116) were excluded. The
remaining surviving patients (n=710) were approached in
writing and asked to complete the MQ 4 weeks post-PCI,
which, in the remainder of the article, will be referred to as
baseline; 536 (response rate, 75%) agreed to participate.
Patients were followed up for clinical adverse events for
2 years.Excluded patients and nonresponders on the MQ were
more likely to smoke (22% vs. 14%; P=.003) but were less
likely to suffer from dyslipidemia (63% vs. 74%; P=.001)
than responders. No other differences were found between
excluded/nonresponders and responders on baseline char-
acteristics, including cardiac medication.
The hospital medical ethics committee approved the
protocol. All patients provided written informed consent,
and the study was carried out to conform with the
Helsinki Declaration.
Demographic and clinical variables
Demographic variables comprised sex and age. Informa-
tion on clinical variables, [i.e., indication for PCI (stable or
unstable angina), previous MI, previous coronary artery
bypass graft (CABG) surgery, previous PCI, stent type
(paclitaxel-eluting stent or other), multivessel disease,
hypertension, dyslipidemia, diabetes mellitus, smoking,
and cardiac medications such as aspirin, angiotensin-
converting enzyme (ACE) inhibitors, h-blockers, diuretics,
and statins] was obtained from medical records.
Fatigue, depressive symptoms, and hopelessness
The 21-item MQ, administered at baseline, was used to
evaluate overall vital exhaustion and symptoms of fatigue,
depression, and hopelessness [10]. Items were answered on
a 3-point scale (0=no, 1=?, 2=yes), with the total score
ranging from 0 to 42. The reliability of the total scale is
good (Cronbach’s a=.89) [5]. Research suggests that the
MQ predominantly assesses two symptom dimensions:
fatigue and depression [11].We could replicate these findings
in the current study (Table 1). A principal components
analysis (varimax rotation with scree plot criterion to
determine the number of factors to extract) indicated two
dominant dimensions, and both scales had good internal
consistency, as measured by Cronbach’s a: (I) fatigue (seven
items; Cronbach’s a=.87; variance=36.4%) and (II) depres-
sive symptoms (seven items; Cronbach’s a=.83; var-
iance=8.0%). Hopelessness was assessed with Item 10 of
the MQ (i.e., bHave you experienced a feeling of hope-
lessness recently?Q). Previous studies have also used one or
two items to assess hopelessness as a risk factor for the onset
of CAD [7,8,17,18].
Clinical end point
The end point was defined as a clinical adverse event
(all-cause mortality or nonfatal MI) 2 years post-PCI.
Statistical analysis
Comparisons of baseline characteristics stratified by
hopelessness (using the highest tertile to indicate a high
score) were performed using chi-square test (Fisher’s exact
test, when appropriate) for nominal variables and Student’s
t test for independent samples for continuous variables.
Table 1







1. Do you often feel tired? .76 0.69 1
2. Do you have a feeling that you
have not been accomplishing
much lately?
.75 0.69 5
3. Do you feel weak all over? .71 0.69 4
4. I feel fine (reverse). .71 0.68 14
5. Do you feel more listless
lately than before?
.68 0.67 8
6. Do you have a feeling these
days that you just do not
have what it takes any more?
.65 0.58 17
7. Do you sometimes feel that
your body is like a battery




Depressive symptoms (Factor II)
1. Would you want to be
dead at times?
.76 0.57 16
2. Do you feel you want
to give up trying?
.72 0.59 13
3. Do you feel dejected? .68 0.66 18
4. Do you believe that you have
come to a bdead endQ?
.66 0.66 7
5. Do you feel like crying sometimes? .60 0.50 19
6. Have you experienced a feeling
of hopelessness recently?
.56 0.57 10
7. Do you ever wake up with




Factor loadings are presented in italics.
a Corrected item–total correlations (Cronbach’s a=estimate of internal
consistency).
Table 2








Male (%) 68 74 .20
Age in years
[mean (S.D.)]
61 (11) 64 (11) .00244
Married/partner (%) 81 81 1.00
Clinical variables (%)
Paclitaxel-eluting stenta 90 88 .53
Multivessel disease 60 60 1.00
Cardiac historyb 62 52 .044
Hypertension 45 50 .35
Dyslipidemia 73 74 .87
Diabetes mellitus 24 18 .12
Smoking 18 12 .06
Cardiac medication (%)
Aspirin 93 96 .15
ACE inhibitors 16 6 b .001444
h-Blockers 25 21 .26
Diuretics 2 1 .81
Statins 77 73 .39
a Paclitaxel-eluting stent was used as the default stent (i.e., in 89% of
S.S. Pedersen et al. / Journal of Psychosomatic Research 62 (2007) 455–461 457Univariable and multivariable Cox regression analyses were
used to examine the predictive value of the total MQ scale
(21 items) and the MQ subscales fatigue (seven items) and
depressive symptoms (seven items), using both continuous
and dichotomized scores. When using dichotomized scores,
we used the standardized cutoff of z14 for the total MQ
[20] and the highest tertile to indicate clinically manifest
symptoms on the separate fatigue and depressive symptom
dimensions, respectively. In all multivariable analyses, we
adjusted for sex, age, multivessel disease, previous cardiac
history, hypertension, dyslipidemia, diabetes, and smoking.
Hazard ratios (HRs) with 95% confidence intervals (CIs) are
reported. Pb.05 was used to indicate statistical significance.
All tests were two-tailed. All analyses were performed using
SPSS 12.0.1.the total sample). The other stents used were sirolimus-eluting stent (4%),
both paclitaxel-eluting stent and sirolimus-eluting stent (1%), or bare-metal
stent/balloon dilation (6%).




Of the 536 patients, two patients did not have a score on
the hopelessness item of the MQ and were therefore
excluded from further analyses.Baseline characteristics
Baseline characteristics stratified by hopelessness are
shown in Table 2. Patients who scored high on hopelessness
were younger, were more likely to have had a previous
cardiac history, and were more likely to have been
prescribed ACE inhibitors. No other differences on demo-
graphic and clinical characteristics were found between
high-hopelessness patients and low-hopelessness patients.
Fatigue, depressive symptoms, and clinical events
At 2-year follow-up, there were 31 (21 deaths and
10 nonfatal MIs) clinical events.
In univariable analyses using dichotomized scores,
depressive symptoms, but not fatigue, were significantly
associated with the incidence of death and nonfatal MI at
2-year follow-up (Fig. 1). Subjecting these subscales and the
original MQ scale (assessing vital exhaustion, cutoff of
z14) to a multivariable Cox regression analysis using a
stepwise procedure, depressive symptoms (HR=2.69; 95%
CI=1.31–5.55; P=.007), but not fatigue and vital exhaus-
tion, were associated with clinical outcome (Table 3). A
stepwise procedure was chosen in order to extract
the component(s) that exerted the most toxic influence
on prognosis.
Fig. 1. Death/MI stratified by fatigue and depressive symptoms. *Numbers
are presented on top of bars.
Table 4
Predictive value of specific depressive items in relation to death/MI at
2 years post-PCIa
HR [95% CI] P
1. Hopelessness (MQ 10) 1.89 [1.31–2.74] .00144
2. Wanting to be dead (MQ 16) 1.59 [1.07–2.37] .024
3. Feeling dejected (MQ 18) 1.24 [0.83–1.85] .30
4. Feeling like crying (MQ 19) 1.19 [0.81–1.75] .38
5. Waking up exhausted (MQ 20) 1.16 [0.80–1.69] .43
6. Wanting to give up trying (MQ 13) 1.15 [0.77–1.71] .50
7. Coming to a bdead endQ (MQ 7) 1.07 [0.71–1.62] .75
a Univariable analyses, using continuous scores for depressive items.
4 Pb.05.
44 Pb.01.
S.S. Pedersen et al. / Journal of Psychosomatic Research 62 (2007) 455–461458Hopelessness and clinical events
Given the possibility that the predictive value of
depressive symptomatology might be attributed to specific
symptoms such as hopelessness, we performed a series of
univariable analyses using continuous scores of the items.
Only the symptoms bhopelessnessQ and bwanting to be
deadQ were significant predictors of death/MI (Table 4). In a
multivariable analysis with a stepwise procedure subjecting
all depressive symptom items as continuous scores, the
only symptom that was retained was bhopelessnessQ (MQ
10; HR=1.93; 95% CI=1.33–2.80; P=.001). Since
bhopelessnessQ and bwanting to be deadQ (i.e., the only
two items that were significant predictors in univariable
analyses) could potentially be equally important cardiotoxic
depressive symptoms, we entered both in a multivariable
analysis, together with baseline characteristics. However,
only hopelessness (HR=1.91; 95% CI=1.28–2.86; P=.02),
but not bwanting to be deadQ (HR=0.97; 95% CI=0.62–
1.48; P=.88), was associated with adverse clinical eventsTable 3
Baseline symptoms and death/MI (31 events) at 2 years post-PCI
HR [95% CI] P
(A) Univariable analysis
Subscale scores
Fatigue 1.35 [0.67–2.74] .40
Depressive symptoms 2.69 [1.31–5.55] .00744
Total MQ score
Vital exhaustion 2.73 [1.17–6.33] .024
(B) Multivariable analysisa
Significant






44 Pb.01.on follow-up. After dichotomizing the hopelessness symp-
tom, with the highest tertile representing clinically manifest
symptomatology, the incidence of clinical events was 11%
(20 of 187) in high-hopelessness patients versus 3% (11 of
347) in low-hopelessness patients (P=.001). Hopelessness
was associated with a more than three-fold risk (HR=3.44;
95% CI=1.65–7.19; P=.001) of adverse clinical outcome in
univariable analysis (Fig. 2).
Entering the hopelessness symptom together with the rest
of the subscale comprising the six other depression symptoms
showed that hopelessness was an independent predictor
of clinical events (HR=4.07; 95% CI=1.76–9.43; P=.001),
whereas the six-item depression score was no longer
associated with death/MI (HR=0.73; 95% CI=0.32–1.63;
P=.44). In multivariable analysis, hopelessness (HR=3.36;
95% CI=1.58–7.14; P=.002) remained an independent
predictor of death/MI and was associated with a more than
three-fold increased risk, adjusting for sex, age, multivessel
disease, previous cardiac history, hypertension, dyslipidemia,
diabetes, and smoking.
In the final analysis, we investigated whether the addition
of hopelessness to a multivariable model, comprising
demographic and clinical baseline characteristics, improved
the level of prediction of death and MI on follow-up. As
indicated by the 2 log likelihood function, the level ofFig. 2. Death/MI stratified by hopelessness. *Numbers are presented on top
of bars.
S.S. Pedersen et al. / Journal of Psychosomatic Research 62 (2007) 455–461 459prediction of the model improved with the addition of
hopelessness [v2=10.420 (df=1), P=.001].Discussion
To our knowledge, this is one of the first studies to
have examined the relative effects of fatigue, depressive
symptoms, and hopelessness on clinical events in patients
with established CAD. In PCI patients treated with
paclitaxel-eluting stents, we found that depressive symp-
toms, but not fatigue, were associated with adverse clinical
outcomes, with the most cardiotoxic depressive symptom
being hopelessness. Hopelessness was associated with a
three-fold increased risk of death/nonfatal MI at 2 years in
adjusted analyses.
The last decade has witnessed a surge in research on
depression as a risk factor for CAD, leading to a call for the
recognition of depression as an established risk factor [13].
Despite extensive research, we still know little about the
nature of depressive symptoms and those that are most toxic
in terms of predicting clinical outcomes. Hence, identifica-
tion of the core and most toxic symptoms of depression is
now receiving increased attention [1,2,21]. However,
studies to date have been rather heterogeneous in their
focus, ranging from deriving subscales from the Beck
Depression Inventory (BDI) and relating them to clinical
outcome [1], to comparing the predictive validity of
instruments (BDI vs. the depression subscale of the Hospital
Anxiety and Depression Scale) [2], to assessing whether
depressive cognitions comprise an underpinning of depres-
sion in post-MI patients [21].
In the current study, we identified hopelessness as the
depressive symptom that was most salient in predicting
prognosis. PCI patients who scored high on hopelessness, as
measured by one item on the MQ, had a more than three-
fold increased risk of mortality and nonfatal MI 2 years
postprocedure, independent of baseline demographic and
clinical characteristics. Previous epidemiological studies
also found that hopelessness was associated with the
progression of carotid atherosclerosis [17,18], morbidity,
and mortality [7,19], but to our knowledge, only one study
has examined the impact of hopelessness as a risk factor in
patients with established CAD [8]. In the latter study,
hopelessness was also associated with decreased survival
and was shown to exert an independent effect on prognosis
relative to depressive symptoms. However, the study did not
compare the influence of fatigue relative to depressive
symptoms and hopelessness.
Physiological pathways through which hopelessness
may exert its deleterious effect on health include decreased
heart rate variability (particularly reduced vagal tone or
parasympathetic activity) [22], impaired fibrinolysis [23],
and inflammation [17]. In the latter study, plasma
fibrinogen, a marker of systemic inflammation, was shown
to mediate the relationship between hopelessness andprogression of carotid atherosclerosis. Compliance may
comprise a behavioral pathway, given that depression has
been shown to have a negative influence on adherence to
cardiac rehabilitation [24] and medication [25]. However,
whether these results extend to hopelessness needs to be
confirmed in future studies.
Given the relatively high prevalence of fatigue and its
deleterious effects on health [3–5,9], it is surprising that
fatigue has not received more attention in the cardiovascular
literature. Although we were not able to confirm that fatigue
was associated with adverse prognosis in the current study,
it is too premature to write off fatigue as a risk factor in
CAD. The reason for the nonsignificant result may be due to
the relatively small number of events in the current study, as
the incidence of death and nonfatal MI was larger in
fatigued patients than in nonfatigued patients. As voiced by
others, there is an urgent need to develop measures of
fatigue that tap these symptoms in patients with cardiac
conditions without the confounding of related symptoma-
tology [11]. With the availability of such measures, it will be
possible to establish the salience of fatigue as a predictor of
clinical events in CAD.
The findings of the current study have implications for
research and clinical practice. Given that there is an inverse
relationship between the length of a questionnaire and the
response rate [26], when collating a test battery, it may be
important to prioritize the inclusion of a measure of
hopelessness if there is no room for a more lengthy measure
of depressive symptoms. A two-item measure of depressive
symptoms [i.e., the Patient Health Questionnaire (PHQ-2)],
which includes hopelessness, has previously been shown to
have good sensitivity and specificity, compared with the
gold standard of a clinical diagnosis of depression, and to be
sensitive to change [27]. The recent four-item Symptoms of
mixed Anxiety–Depression Index (SAD4) also includes
hopelessness [28] and has been shown to predict a clinical
diagnosis of depression even when adjusting for depressive
symptomatology, as measured by the BDI. However, neither
the PHQ-2 nor the SAD4 has yet been used as a potential
predictor of clinical outcome in CAD. In terms of clinical
practice, screening for hopelessness is feasible and can be
incorporated into the daily routine of practicing cardiolo-
gists. PCI patients suffering from hopelessness need to be
identified early on and to be followed more closely
throughout in order to motivate them to participate in
cardiac rehabilitation, as they may be more inclined to
refuse participation or to drop out from rehabilitation
programs [24]. In terms of intervention, it may be possible
to reduce feelings of hopelessness using a cognitive–
behavioral approach either on its own or in combination
with pharmacotherapy, as hopelessness is predominantly
considered a cognitive symptom of depression [29,30].
The current study has some limitations. First, for 42%
of the patients, we had no information on left ventricular
ejection fraction; therefore, in multivariable analyses, we
were not able to adjust for measures of disease severity
S.S. Pedersen et al. / Journal of Psychosomatic Research 62 (2007) 455–461460but only for a measure of the extent of disease, as assessed
by multivessel disease. Second, results may not be
generalizable to MI patients, since only patients with
stable or unstable angina as an indication for PCI were
included. Nevertheless, the results of this study show that
the assessment of psychosocial risk factors is also
important in more low-risk patients, such as patients with
angina, given their impact on adverse clinical events.
Third, 25% of patients declined to participate. However,
nonresponders and excluded patients (excluded due to lack
of language proficiency) did not differ from responders on
demographic and clinical baseline characteristics, except
for nonresponders/excluded patients being more likely to
smoke and less likely to suffer from dyslipidemia. Fourth,
our multivariable model was overfitted given the number
of adverse clinical events. Fifth, hopelessness was assessed
by one item, but other studies have also used a one-item
measure of hopelessness and have shown that hopelessness
is a predictor of adverse clinical outcome [8]. Finally,
although it may seem contrary to expectations that the
item bDo you ever wake up with a feeling of exhaustion
and fatigue?Q loaded on the depression factor rather than
on the fatigue factor, insomnia and fatigue both form part
of the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition diagnostic criteria for a major
depressive disorder.
In conclusion, we found that depressive symptoms, but
not fatigue, were associated with adverse clinical outcome
in PCI patients treated with paclitaxel-eluting stents. More
specifically, hopelessness proved to be the most cardiotoxic
component and was associated with a more than three-fold
increased risk of death and nonfatal MI at 2 years, after
adjusting for demographic and clinical baseline character-
istics. It is feasible to include the assessment of hopelessness
in research protocols and clinical practice. Future studies
that replicate these findings are warranted, given that few
studies have examined the impact of hopelessness on
patients with established CAD.Acknowledgments
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